BergaCare SmartLipids: commercial lipophilic active concentrates for improved performance of dermal products

• Florence Olechowski,
• Rainer H. Müller and
• Sung Min Pyo

Beilstein J. Nanotechnol. 2019, 10, 2152–2162, doi:10.3762/bjnano.10.208

• reduction of side effects (e.g., skin irritation through sensitizing active agents), which improves the skin tolerability. Regulatory aspects, such as submicron particle status, excipients, and certifications, are also discussed. Keywords: chemical stabilization of active agents; controlled release; firm

• cream, the melting enthalpy will decrease. Thus, the physical stability of SmartLipids is easy to analyze and to prove. Chemical stabilization of active agents Classical fluid carriers such as nanoemulsion and liposomes have a limited ability to protect labile lipophilic active agents. Due to the

• stabilization of active agents. General features of all lipid nanoparticles are the restauration of the natural protective lipid barrier, and penetration enhancement with increased dermal bioavailability and controlled/optimized release. Even if a different carrier system is superior in one or two properties